Final five-year results from the ENDEAVOR III trial, comparing the Endeavor Zotarolimus-Eluting Coronary Stent to the Cypher Sirolimus-Eluting Coronary Stent, showed Endeavor had lower long-term rates of adverse events, cardiovascular death and heart attacks. The results were released last week during the American College of Cardiology’s 59th Scientific Session.

The GuideLiner catheter is a coaxial “mother and child” guide extension using a rapid exchange system that provides back-up support and selective deep intubation in challenging coronary interventions. The catheter is available in 6, 7 and 8 French sizes.

A new and improved design of the original Gopher catheter, the Gopher Gold is designed for use when treating coronary and peripheral stenoses over an existing in-place 0.014-inch guide wire.

The Merit Laureate hydrophilic guide wire is designed for drainage catheter access, dialysis catheter placement, as well as difficult vascular access procedures.

March 24, 2010 – A team of Mayo Clinic researchers found that cardiac rehabilitation is associated with significantly reduced mortality rates for patients who receive coronary stents. The findings were presented last week at the annual meeting of the American College of Cardiology in Atlanta.

March 24, 2010 – Enrollment began this week in the CITADEL, which is the second of two large-scale, prospective, multicenter studies comparing implantable electrophysiology device infection rates. The study will look at patients with and without a new anti-bacterial envelope covering their devices.

March 23, 2010 – Frost and Sullivan gave a 2010 North American New Product Innovation Award to Positron Corp. for its pioneering cardiac positron emission tomography (PET) scanner, the Attrius.

March 24, 2010 – The 2010 Annual Meeting of the American Association for Thoracic Surgery (AATS) will showcase two multipurpose interventional operating room suites that integrate digital imaging diagnostics, catheterization, and surgical capabilities.

March 23, 2010 – The U.S. Food and Drug Administration (FDA) recently added a boxed warning to the anti-blood clotting drug Plavix (clopidogrel), alerting patients and healthcare professionals that the drug can be less effective in people who cannot metabolize the drug to convert it to its active form.


March 18, 2010 – The U.S. Food and Drug Administration (FDA) today added a boxed warning to the anti-blood clotting drug Plavix (clopidogrel), alerting patients and healthcare professionals that the drug can be less effective in people who cannot metabolize the drug to convert it to its active form.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now